Relmada Therapeutics (RLMD) reports $234M cash, 76% durable response for NDV01, and plans Phase 3 Rescue Program in mid-2026.

Key Takeaways

• First quarter cash balance increased to $234 million, compared to $94 million at the end of Q4 2025.
• Completed a $160 million private placement financing, strengthening the company’s balance sheet.
• NDV01 showed a 95% complete response rate at any time and a 76% durable response rate at 12 months among high-risk NMIBC patients.
• FDA alignment achieved for the Phase 3 Rescue Program, expected to initiate in mid-2026.
• Net loss for Q1 2026 was $19.1 million ($0.22 per share), compared to a net loss of $17.6 million ($0.58 per share) for Q1 2025.

Financial Performance

Relmada Therapeutics, Inc. reported its earnings for the first quarter of 2026, highlighting a significant improvement in its financial standing. The company ended the quarter with a robust cash balance of $234 million, a notable increase from $94 million at the close of 2025. This increase is attributed to the completion of a $160 million private placement financing announced in March 2026. With these funds, the company expects to have sufficient runway to support its operations through 2029, including the advancement of its Phase 3 Rescue Program for NDV01.

In terms of expenses, research and development costs totaled $8.1 million for the quarter, a decrease from $12 million in the same period last year. This drop was primarily due to non-recurring costs related to the previous year’s acquisitions. Conversely, general and administrative expenses rose to $11.4 million, up from $6.3 million in Q1 2025, driven largely by increased compensation costs.

Overall, the company reported a net loss of $19.1 million, or $0.22 per share, compared to a net loss of $17.6 million, or $0.58 per share, in the first quarter of 2025. Despite the losses, the financial results indicate a firm foundation for future growth and strategic initiatives.

Strategic Initiatives

During the earnings call, CEO Dr. Sergio Traversa emphasized the progress made with NDV01, a novel sustained release intravesical formulation intended for treating non-muscle invasive bladder cancer (NMIBC). Key milestones highlighted include:

• Robust 12-month data from the ongoing Phase 2 study of NDV01, showing a 95% complete response rate and a 76% durable response rate at 12 months among high-risk NMIBC patients.
• Successful alignment with the FDA on the registration plan for the Phase 3 Rescue Program, which will evaluate NDV01 in BCG-unresponsive NMIBC patients and those at intermediate risk.
• A provisional patent application filed in April 2026 that could extend NDV01's commercial exclusivity to 2047, significantly bolstering the company’s intellectual property rights.

Furthermore, Relmada is preparing to launch a proof-of-concept study for Supranolone, targeted at Prader-Willi syndrome, expected to commence in mid-2026. These developments reflect the company's commitment to addressing unmet medical needs and advancing innovative therapies in the oncology and neuroscience sectors.

Future Outlook

Looking ahead, management remains optimistic about the company’s trajectory. The initiation of the Phase 3 Rescue Program for NDV01 in mid-2026 is anticipated to be a transformative moment for Relmada. The Phase 3 program is strategically designed with two separate approval pathways to maximize the chances of success. One pathway focuses on BCG-unresponsive patients, while the other targets intermediate-risk patients following transurethral resection.

The management team expressed confidence that NDV01’s favorable safety profile and high efficacy data will resonate well with both the medical community and potential investors. The upcoming presentations at the American Urological Association (AUA) Annual Meeting are expected to generate significant interest and discussion regarding NDV01, further solidifying its position in the bladder cancer treatment landscape.

In addition to NDV01, the planned studies for Supranolone provide a promising avenue for growth, diversifying the company’s pipeline and enhancing its market positioning.

Closing Assessment

In summary, Relmada Therapeutics, Inc. is making substantial strides in its clinical programs and financial health. The solid performance reported for the first quarter of 2026, combined with promising data for NDV01 and strong financial backing, presents a positive outlook for the company. As they prepare to initiate their Phase 3 Rescue Program and advance other strategic initiatives, investors may find Relmada an intriguing opportunity in the biotech sector, particularly in the treatment of cancer and neuropsychiatric disorders.

This analysis is based on public earnings call materials and is not investment advice.